SCHEMBL6313267

SCHEMBL6313267

Cc1nc2cc(NC(=O)Nc3ccc(C)c(Cl)c3)ccc2s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
NPC1 O15118 4/20 0.56
CASP3 P42574 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
TRPV1 Q8NER1 1/20 0.55
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
HSD17B10 Q99714 1/20 0.53
LDHA P00338 1/20 0.51
KDM4E B2RXH2 2/20 0.51
CA2 P00918 1/20 0.51
POLB P06746 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
MAPT P10636 3/20 0.50
TP53 P04637 1/20 0.50
HTT P42858 1/20 0.50
KDR P35968 1/20 0.50
EPHB4 P54760 1/20 0.50
TEK Q02763 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6308055 0.91 SMN1; SMN2 (0.61) RAB9ASMN1; SMN2NPC1CASP3SENP7
SCHEMBL6305909 0.82 KDR (0.64) RAB9ANPC1CASP3SENP7TRPV1
SCHEMBL6308329 0.82 RAB9A (0.55) RAB9ASMN1; SMN2NPC1CASP3SENP7
SCHEMBL6306822 0.82 RAB9A (0.64) RAB9ASMN1; SMN2NPC1CASP3SENP7
SCHEMBL4920329 0.82 TRPV1 (0.65) RAB9ASMN1; SMN2NPC1CASP3SENP7
SCHEMBL5798843 0.81 RAB9A (0.65) RAB9ASMN1; SMN2NPC1CASP3SENP7
SCHEMBL6314690 0.81 IMPDH2 (0.57) RAB9ASMN1; SMN2NPC1CASP3SENP7
SCHEMBL6305211 0.81 MAPT (0.63) RAB9ASMN1; SMN2NPC1CASP3SENP7
SCHEMBL30577265 0.80 SMN1; SMN2 (0.81) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL4011536 0.79 LDHA (0.78) RAB9ASMN1; SMN2NPC1CASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050119304-A1 Urea derivatives BAYER HEALTHCARE AG (DE) 2005-06-02 US claimed
EP-1465623-A1 UREA DERIVATIVES Bayer HealthCare AG (DE) 2004-10-13 EP claimed
WO-2003055484-A1 UREA DERIVATIVES BAYER HEALTHCARE AG (DE) 2003-07-10 WO claimed
US-20050119304-A1 Urea derivatives BAYER HEALTHCARE AG (DE) 2005-06-02 US disclosed
EP-1465623-A1 UREA DERIVATIVES Bayer HealthCare AG (DE) 2004-10-13 EP disclosed
WO-2003055484-A1 UREA DERIVATIVES BAYER HEALTHCARE AG (DE) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119304-A1 Urea derivatives SLC14A1, UBA1, UFM1 RAB9A 1907/4885SMN1; SMN2 1077/4885NPC1 2788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.